The second aspect is in regards to clause 64(1)(b) which relates to consumer advisory committees. The Minister will be aware that, actually, the legislative requirement around having a consumer panel has existed and is in place at the moment. The reality is, though, that Pharmac has just simply not taken that as far as it could have done, and, actually, the reality of having the clinical committee has really trumped, and the Consumer Advisory Committee, while it has been there, has really been not of any significant substance. But the challenge, going back to point made by the Hon Michael Woodhouse around consumer input and being part of the Health Committee—I see Dr Liz Craig down the back, a fellow member on the Health Committee last year with me—is that of the petitions that you would receive on that, 90 percent of petitions coming through that relate to Pharmac and Pharmac-related drugs. 